Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (20)

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2020

  1. Influence of MUC5B gene on antisynthetase syndrome

    Scientific Reports, Vol. 10, Núm. 1

  2. Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part I: Diagnosis, Evaluation and Treatment

    Reumatologia Clinica, Vol. 16, Núm. 2P1, pp. 71-86

2019

  1. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases

    Arthritis and Rheumatology, Vol. 71, Núm. 12, pp. 2081-2089

  2. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

  3. LAUDES Study: impact of digital ulcers on hand functional limitation, work productivity and daily activities, in systemic sclerosis patients

    Rheumatology International, Vol. 39, Núm. 11, pp. 1875-1882

2018

  1. Successful Optimization of Adalimumab Therapy in Refractory Uveitis Due to Behçet's Disease

    Ophthalmology, Vol. 125, Núm. 9, pp. 1444-1451

  2. Timing of onset affects arthritis presentation pattern in antisynthetase syndrome

    Clinical and Experimental Rheumatology, Vol. 36, Núm. 1, pp. 44-49

2017

  1. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project

    Journal of Clinical Lipidology, Vol. 11, Núm. 3, pp. 749-756.e3

2016

  1. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies

    Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344

  2. LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition

    Clinical and Experimental Rheumatology

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

2013

  1. Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 7, pp. 1233-1238

  2. New insight on the Xq28 association with systemic sclerosis

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 12, pp. 2032-2038

2012

  1. Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis

    Arthritis Research and Therapy, Vol. 14, Núm. 3

  2. Evaluation of a shared autoimmune disease-associated polymorphism of TRAF6 in systemic sclerosis and giant cell arteritis

    Journal of Rheumatology, Vol. 39, Núm. 6, pp. 1275-1279

2011

  1. No evidence for association between the CCR5/Delta32CCR5 polymorphism and systemic sclerosis

    Clinical and Experimental Rheumatology

1996

  1. Registro Nacional de Enfermedades Reumaticas Infantiles

    Anales Espanoles de Pediatria, Vol. 45, Núm. 4, pp. 346-350